

**Xifaxan 550mg (rifamycin)
Effective 07/01/19**

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

FDA Indications

1. Reduction in risk of overt hepatic encephalopathy recurrence in adults
2. Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults

Coverage Guidelines

Xifaxan may be approved when all the following diagnosis-specific criteria has been met and documentation has been provided:

1. Member has a diagnosis of hepatic encephalopathy (550mg) **AND** is currently receiving treatment with Xifaxan excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR

- a. Member has had an inadequate response or has a contraindication to a lactulose product
- b. Member is at least 18 years of age

2. Member has a diagnosis of Irritable Bowel Syndrome with Diarrhea

AND

- a. Member has had an inadequate response or has a contraindication to loperamide or diphenoxylate/atropine **AND** a bile sequestrant (e.g., cholestyramine, colestipol, colesevelam)
- b. Member is at least 18 years of age

Limitations

1. The following quantity limits apply:

Hepatic Encephalopathy	550mg twice a day; 60 tablets per 30 days
------------------------	---



IBS w/Diarrhea	550mg three times a day x 14 days 42 tablets per 14 days – May be treated up to 2 times with this regimen
----------------	--

References

1. Lee S, et al. P142. Presented at: Crohn’s & Colitis Congress; Jan. 19-20, 2018; Las Vegas, NV.
2. Antibiotics for induction and maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2019 Feb 7;2:CD012730. doi: 10.1002/14651858.CD012730.pub2. Townsend CM1, Parker CE, MacDonald JK, Nguyen TM, Jairath V, Feagan BG, Khanna R
3. Xifaxan (rifaximin) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; January 2018
4. Prevalite (cholestyramine) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories Inc; August 2017
5. Lactulose Solution [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co Inc; March 2013
Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer, Inc.; October 2018
6. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735

Review History

06/19/19 – Reviewed

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.